Comparative Pharmacology
Head-to-head clinical analysis: EPITOL versus LAMICTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPITOL versus LAMICTAL.
EPITOL vs LAMICTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbamazepine stabilizes the inactivated state of voltage-gated sodium channels, thereby inhibiting high-frequency repetitive firing of action potentials and reducing synaptic transmission.
Lamotrigine is a triazine antiepileptic drug that inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and modulating presynaptic transmitter release of excitatory amino acids like glutamate and aspartate.
Carbamazepine, immediate-release: initial 200 mg orally twice daily; increase by 200 mg/day at weekly intervals. Typical maintenance: 800-1200 mg/day in 2-3 divided doses. Extended-release: initial 200 mg orally twice daily; maintenance 400-600 mg twice daily.
Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 1 week, then 150 mg twice daily or 200 mg twice daily (if taking valproate, reduced regimen).
None Documented
None Documented
20-40 hours (mean 30 hours); linear kinetics at therapeutic doses; decreased with concomitant enzyme-inducing drugs
14 hours (monotherapy); 7 hours (with enzyme-inducers); 30 hours (with valproate).
Renal: 70% (as glucuronide conjugates and other metabolites), Fecal: 30% (unchanged and metabolites)
Renal (70% as glucuronide metabolites, 2% as unchanged drug); fecal (2%); biliary (minor).
Category C
Category C
Anticonvulsant
Anticonvulsant